Parkinson’s Disease | Treatment Algorithms: Claims Data Analysis | US | 2025

Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including dopamine precursors, dopamine agonists, and MAO-B inhibitors. PD treatment requires individualized care, a high level of polypharmacy, and frequent adjustments as patients progress through lines of therapy. Numerous branded agents targeting niche subpopulations with high unmet need (e.g., Inbrija [Merz], Gocovri [Supernus], Nourianz [Kyowa Kirin]) have entered the market, which is dominated by entrenched generic standards of care. The market is poised to further expand as new drugs offering potential clinical improvements (e.g., AbbVie’s Vyalev, Amneal’s Crexont) gain traction. Understanding the treatment dynamics in competitive segments of the PD therapy market will be crucial for drug developers and marketers of in-line products.

QUESTIONS ANSWERED

• ·What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PD patients?
• What percentage of PD patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of PD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.

Markets covered: United States

Key companies: AbbVie, Acadia, Amneal, Kyowa Kirin, Lundbeck, Merz, Supernus

Key drugs: Duopa, Gocovri, Inbrija, Neupro, Northera, Nourianz, Nuplazid, Ongentys, Rytary, Xadago, all generic mainstays